“…Currently, only selected COXIBs such as celecoxib, etoricoxib, or the prodrug parecoxib are on the market due to an increased risk for cardiovascular incidents such as stroke and heart attacks described after long-term treatment with, e.g., rofecoxib or valdecoxib. In this context, ongoing efforts are made to identify COXIBs with optimized pharmacological properties, among them are molecular hybrids, such as dual inhibitors targeting simultaneously the COX and LOX pathway [ 14 , 15 ] or, additionally, releasing gasotransmitters such as H 2 S [ 16 ] or, as targeted herein, nitric oxide (NO • ) [ 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ].…”